Commissie Voor Klinisch Toegepast Onderzoek - Developmental Therapeutics Review - Q4 2010

Global Markets Direct, December 2010, Pages: 39

Commissie Voor Klinisch Toegepast Onderzoek – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Commissie Voor Klinisch Toegepast Onderzoek - Developmental Therapeutics Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Commissie Voor Klinisch Toegepast Onderzoek - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Commissie Voor Klinisch Toegepast Onderzoek human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Commissie Voor Klinisch Toegepast Onderzoek with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Commissie Voor Klinisch Toegepast Onderzoek’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Commissie Voor Klinisch Toegepast Onderzoek’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Commissie Voor Klinisch Toegepast Onderzoek in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Commissie Voor Klinisch Toegepast Onderzoek’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Commissie Voor Klinisch Toegepast Onderzoek.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Commissie Voor Klinisch Toegepast Onderzoek and identify potential opportunities in those areas.

List of Tables
List of Figures
Commissie Voor Klinisch Toegepast Onderzoek Snapshot
Key Information
Key Facts
Commissie Voor Klinisch Toegepast Onderzoek – Research and Development Overview
Key Therapeutic Areas
Commissie Voor Klinisch Toegepast Onderzoek – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Commissie Voor Klinisch Toegepast Onderzoek – Pipeline Products Glance
Commissie Voor Klinisch Toegepast Onderzoek – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Commissie Voor Klinisch Toegepast Onderzoek Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Commissie Voor Klinisch Toegepast Onderzoek – Drug Profiles
Carboplatin + Taxol
Product Description
Mechanism of Action
R&D Progress
Chlorambucil For Follicular lymphoma
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Dexamethasone + Adriamycin + Melphalan + Thalidomide + Peripheral Blood Stem Cell Transplantation
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Doxorubicin + Etoposide
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Doxorubicin Hydrochloride + Prednisone + Vincristine Sulfate + Filgrastim
Product Description
Mechanism of Action
R&D Progress
dexamethasone + cisplatin + cytarabine + etoposide + ifosfamide + methotrexate
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + Cisplatin + Cytarabine + Etoposide + Ifosfamide + Methotrexate + Rituximab
Product Description
Mechanism of Action
R&D Progress
R-CHOP + Filgrastim
Product Description
Mechanism of Action
R&D Progress
Imatinib + Cytarabine
Product Description
Mechanism of Action
R&D Progress
Commissie Voor Klinisch Toegepast Onderzoek – Pipeline Analysis
Commissie Voor Klinisch Toegepast Onderzoek – Pipeline Products by Therapeutic Class
Commissie Voor Klinisch Toegepast Onderzoek Pipeline Products By Target
Commissie Voor Klinisch Toegepast Onderzoek – Pipeline Products by Route of Administration
Commissie Voor Klinisch Toegepast Onderzoek – Pipeline Products by Molecule Type
Commissie Voor Klinisch Toegepast Onderzoek – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Charter Schools - Global Outlook
• Sports and Fitness Nutrition - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• International Military and Government Helicopter Survey
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles